Zanelli Magda, Sanguedolce Francesca, Zizzo Maurizio, Ricci Stefano, Bisagni Alessandra, Palicelli Andrea, Fragliasso Valentina, Donati Benedetta, Broggi Giuseppe, Boutas Ioannis, Koufopoulos Nektarios, Foroni Moira, Coppa Francesca, Morini Andrea, Parente Paola, Zuccalà Valeria, Caltabiano Rosario, Fabozzi Massimiliano, Cimino Luca, Neri Antonino, Ascani Stefano
Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Int J Mol Sci. 2024 Dec 9;25(23):13213. doi: 10.3390/ijms252313213.
In this article, we provide a review of large B-cell lymphomas (LBCLs), comparing the recently published fifth edition of the WHO classification and the International Consensus Classification (ICC) on hematolymphoid tumors. We focus on updates in the classification of LBCL, an heterogeneous group of malignancies with varying clinical behaviors and different pathological and molecular features, providing a comparison between the two classifications. Besides the well-recognized diagnostic role of clinical, morphological and immunohistochemical data, both classifications recognize the ever-growing impact of molecular data in the diagnostic work-up of some entities. The main aim is to offer a guide for clinicians and pathologists on how the new classifications can be applied to LBCL diagnosis in routine practice. In the first part of the paper, we review the following categories: LBLs transformed from indolent B-cell lymphomas, diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), double-hit/triple-hit lymphomas (DH/TH), high-grade large B-cell lymphoma, not otherwise specified (HGBCL, NOS), LBCL with rearrangement, Burkitt lymphoma (BL) and HGBCL/LBCL with aberration, focusing on the differences between the two classifications. In the second part of the paper, we provide a practical diagnostic algorithm when facing LBCLs in routine daily practice.
在本文中,我们对大B细胞淋巴瘤(LBCL)进行了综述,比较了最近发布的世界卫生组织(WHO)第五版分类和血液淋巴肿瘤国际共识分类(ICC)。我们重点关注LBCL分类的更新,LBCL是一组异质性恶性肿瘤,具有不同的临床行为以及不同的病理和分子特征,并对这两种分类进行了比较。除了临床、形态学和免疫组化数据公认的诊断作用外,两种分类都认识到分子数据在某些实体诊断检查中日益增长的影响。主要目的是为临床医生和病理学家提供指导,说明如何在常规实践中将新分类应用于LBCL诊断。在本文的第一部分,我们回顾以下类别:由惰性B细胞淋巴瘤转化而来的LBL、弥漫性大B细胞淋巴瘤,非特指型(DLBCL,NOS)、双打击/三打击淋巴瘤(DH/TH)、高级别大B细胞淋巴瘤,非特指型(HGBCL,NOS)、伴有 重排的LBCL、伯基特淋巴瘤(BL)以及伴有 畸变的HGBCL/LBCL,重点关注两种分类之间的差异。在本文的第二部分,我们提供了在日常常规实践中面对LBCL时的实用诊断算法。